The drug Omnitus is characterized by instructions as an
antitussive agent with a pronounced bronchodilating, expectorant and anti-inflammatory effect. The use of this medicine can significantly improve blood oxygenation and spirometry. In addition, the Omnitus preparation (the instruction explains this with the action of the active component) has a direct effect on the cough center. If we talk about the main pharmacokinetic characteristics of this bronchodilating and anti-inflammatory drug, then after ingestion, its highest plasma concentration is noted after two to seven hours (depending on dosage), and the half-life is about six to ten hours.
The antitussive drug Omnitus is issued (the instructions for it confirm this) in the form of biconvex tablets of yellow-orange and red color, as well as in the form of a transparent syrup with a characteristic smell of vanilla. The first as the main component may include 20 or 50 mg of butamirate citrate.
Additional elements are hypromellose, macrogol, lactose monohydrate, black dye, silicon dioxide, talc, povidone,
magnesium stearate, ethyl cellulose,
titanium dioxide, dye azorubine, as well as yellow, crimson or brown dye. Omnitus Cough Syrup contains 0.8 mg of
butamirate citrate, 70% sorbitol, sodium saccharinate, vanillin, 96% ethanol,
benzoic acid, sodium hydroxide and anise oil. In a small amount, glycerol and purified water are present in it.
To use an expectorant and bronchodilating medicine "Omnitus" the instruction advises to eliminate a dry cough of any etiology. For example, this anti-inflammatory agent helps very well and quickly with flu, whooping cough, and a variety of colds. In addition, this antitussive drug is actively prescribed to suppress cough during bronchoscopy, surgical interventions, as well as in the preoperative and postoperative periods.
The manufacturer categorically does not recommend the use of this anti-inflammatory drug in the case of an allergic reaction to butamirate citrate in the patient, as well as with increased sensitivity to any of the auxiliary components present in its composition. Women who have a baby should refuse to take the antitussive drug Omnitus. These tablets should also not be taken while breastfeeding a newborn baby. And finally, it is not allowed to prescribe this bronchodilating agent to small patients - children under the age of three.
If we consider the main side effects that can be triggered by the use of the drug Omnitus, then first of all it is necessary to highlight a rather high risk of diarrhea, nausea and exanthema. Dizziness, flushing of the skin, rash, itching, and hives may occur.